Waterman 2018.
Study characteristics | ||
Methods |
Design: implementation and evaluation of intervention. Qualitative interviews with intervention providers Country: Sierra Leone Study aims:
Study recruitment details: study comprised 3 phases of intervention. Participants completing 1 phase were screened and, if appropriate, referred to the next phase. In addition a number of new participants entered the study direct into Phase 2. In addition, 9 people involved in delivery of the group CBT were recruited for an interview to explore barriers and enablers. Setting: ETCs set up across Sierra Leone and staffed by a combination of national and international HCWs Epidemic/pandemic disease: EVD Phase of disease outbreak: during the outbreak |
|
Participants |
Total study population: people trained to facilitate group CBT: 12 (9 were interviewed). Phase 1: 3273 invited to attend. 1533 attended. Phase 2: 1170 referred from phase 1 + 1720 joined at this point. Total participants attending sessions = 2533. Phase 3: 523 screened, 298 referred, 253 attended intervention, 157 completing post‐intervention assessment.
Inclusion criteria: ETC staff member from 1 of the 6 ETCs within Sierra Leone
Exclusion criteria: none stated
Type (profession) of staff: not reported for Phase 1 or 2. For Phase 3 ‐ "136 were unemployed (53.80%), 80 were employed (31.60%) and 32 (12.60%) were students." Profession not stated Length of time in the profession: not reported Previous experience of working in the frontline during an epidemic/pandemic: not reported Details of who the frontline staff were providing care for: patients attending ETCs. There were 6 ETCs ‐ 5 were 100‐bed facilities and 1 had 62 beds |
|
Interventions | 1. Name of intervention: (Phase 1, n = 1533; Phase 2, n = 2533; Phase 3, n = 157 completers; attended all 3 phases, n = 75)
|
|
Outcomes |
Outcomes: 7‐item well‐being screening tool concerning stress, sleep, anxiety, depression, relationship difficulties, behavioural changes and PTSD
Data collection: 7‐item well‐being screening tool was assessed before Phase 1 Other outcomes were measured at the start of Phase 2, at the start of Phase 3, and 2 weeks after completion of Phase 3. "Participants who had been the most symptomatic at Phase 1 were re‐screened using GAD7 and PHQ9 2 months after the completion of Phase 2". In addition there was data from 9 interviews (45‐60 min long). |
|
Funding | Funding statement: financial support was received from the UK Public Health Rapid Support Team, funded by the UK Government, the UK Department for International Development and the Maudsley Charity. This report is independent research by the UK Public Health Rapid Support Team Conflict of interest: study authors report no conflict of interest | |
Notes | Included in the review of qualitative evidence synthesis. Classified as a 'descriptive study', as descriptive data were used from this mixed‐method study. Methodological assessment: assessed using WEIRD tool Overall assessment: minor limitations. For details of assessment see Table 10, and for support for judgements see Appendix 14. |
AHP: allied health professional; CASP: Critical Appraisal Skills Programme; CBT: cognitive behavioural therapy; CDC: Centers for Disease Control and Prevention; CD‐RISC: Connor Davidson Resilience Scale; DSRT: Deployment Safety Resilience Team; ED: emergency department; ETC: Ebola treatment centres; EVD: Ebola virus disease; GAD‐7: General Anxiety Disorder‐7; HCW: healthcare worker; ICU: intensive care unit; IES(‐R): Impact of Event Scale (‐Revised); K‐10: Kessler Psychological Distress Scale (10‐item); MERS: Middle East respiratory syndrome; MBI: Maslach Burn‐out Inventory; PC‐PTSD: Primary Care Post‐traumatic Stress Disorder Screen; PFA: psychological first aid; PHQ‐9: Patient Health Questionnaire‐9; PPE: personal protective equipment; PPI: personal and public involvement; ProQOL 5: Professional Quality of Life scale; PTSD: post‐traumatic stress disorder; SARS: severe acute respiratory syndrome; SD: standard deviation; VRE: virtual reality environment; WEIRD: Ways of Evaluating Important and Relevant Data; WHO: World Health Organization